An observational study in Sepsis and Sepsis Bacterial, sponsored by Abionic SA. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-25.
Sponsored by Abionic SA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 208 studies in Sepsis with a site in France — 40 open to participants now, 45 under way, 5 of them phase 3. Sepsis · France.
Among the 208 studies in Sepsis with a site in France, this one is the 79th largest by enrollment of the 97 observational ones that give a count, is one of 7 that started in 2022, is one of 97 observational ones, and was the 159th registered.
2,417 studies on the registry are indexed under Sepsis; 542 are open to participants now.
Browse Sepsis studies →40 of the 208 studies in Sepsis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 18+
Deepull Diagnostics S.L. · Sites in France, United States, Germany and 2 more countries
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 37 wk+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
208 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 31 · Phase 4 10
First in 1997; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 150 across 1,162 observational studies indexed under Sepsis.
Median enrollment 149 across the 110 interventional studies, 170 across the 97 observational. Of the 140 that completed or were terminated, 13 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 208 have an industry lead sponsor. The 10 most frequent:
Abionic SA is the lead sponsor of 8 studies on the registry; none are open to participants now.
Abionic SA has 5 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
15 of the studies in Sepsis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05843786Phase 3Hospices Civils de LyonHuman Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients | 2027-07-30 |
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT04513288Rennes University HospitalICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock | 2026-11-20 |
| NCT06219135Hospices Civils de LyonEvaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis | 2026-11-21 |
| NCT06854640BayerA Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy | 2026-12-25 |
Add all 15 to your calendar (.ics) → With an account.
Among the 208 studies in Sepsis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Abionic has developed a targeted, rapid test for pancreatic stone protein (PSP) in human K2-EDTA venous whole blood using the abioSCOPE instrument.
Currently no PSP study comparaison has been done between venous and arterial whole blood. Abionic would like to confirm the equivalence of the PSP between venous whole blood and arterial whole blood.
Patients admitted at the hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood samples will be collected for the PSP measurement using the abioSCOPE.
Primary assessment
Pairwise comparability of test results when performed with K2-EDTA anticoagulated venous whole blood or K2-EDTA anticoagulated arterial whole blood, represented as percent recovery of arterial whole blood compared to venous whole blood, as well as scatter plots with Weighted Deming and Passing Bablok Regression, and bias plots.
Time frame: through study completion, an average of 1.5 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Oct 2022, 1 month.
Of 52 industry-sponsored observational studies under Sepsis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 44. This study's 1 month is below that.
Counting every sponsor, half of 544 studies reached it within 27 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abionic SA